With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed in your inbox four mornings each week so you can quickly down and digest the day's most pertinent cancer news.
Yesterday the FDA approved pembrolizumab as first-line therapy in combo with chemo for metastatic or recurrent/refractory cervical cancer based on the recently published results of KEYNOTE-826. | FDA 2021